KalVista Pharmaceuticals (KALV)

• Market cap: $551M
• 1 day: -0.55%
• 5 days: -1.98%
• 1 month: -10.43%
• 3 months: -19.96%
• 6 months: -20.77%
• Year to date: 23.14%
• 1 year: 6.23%
• 5 years: -35.29%
• 10 years: -80.57%
• Sector: Healthcare
• Industry: Biotechnology

About: KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Employees: 270